|
|
|
Company
|
2/19/06 Price
|
5/01/06
Price
|
% Chng.
|
Key product
|
|
|
$29.80
|
$31.10
|
4.36%
|
Symmetrel, FDA-approved to treat influenza A *
|
|
|
$4.96
|
$1.87
|
(62.29)%
|
Rec'd $6M grant from U.S. to develop H5N1 vaccine
|
|
|
$6.10
|
$5.04
|
(17.38)%
|
Imunostimulatory sequence technology to target virus
|
|
|
$4.20
|
$4.87
|
15.95%
|
Developing DNA-based vaccine vs. H5N1
|
|
|
$1.84
|
$1.18
|
(35.87)%
|
Announced plans to research H5N1 vaccine
|
|
|
$7.55
|
$2.64
|
(65.03)%
|
Antisense-based therapeutic
|
|
|
$24.96
|
$25.30
|
1.36%
|
PER.C6 tech used by Sanofi in H5N1 vaccine development
|
|
|
$3.14
|
$1.62
|
(48.41)%
|
Alferon, stimulates Interferon to defend vs. H5N1
|
|
|
$4.60
|
$2.86
|
(37.83)%
|
Technology may help speed H5N1 vaccine development
|
|
|
$19.07
|
$8.50
|
(55.43)%
|
Peramivir, which may inhibit H5N1 virus
|
|
|
$14.04
|
$18.77
|
33.69%
|
Announced plan to develop RNAi therapeutic for H5N1
|
Generex Biotechnology
(GNBT, news, msgs)
|
$1.62
|
$1.60
|
(1.23)%
|
Developoing anti-H5N1 vaccine w/ Antigen Express tech
|
|
|
$1.61
|
$0.52
|
(67.70)%
|
Microarray for typing flu viruses
|
|
|
$13.51
|
$17.68
|
30.87%
|
DNA test for flu viruses
|
|
|
$4.15
|
$3.12
|
(24.82)%
|
Anflu, licensed in China as antiflu vaccine
|
